Our next evaluation of the performance of the three methods used biologically, a priori defined gene sets and three microarray datasets considered in Subramanian et al. [3], download from GSEA web-page, [9]: 17 p53 wild-type vs. 33 p53 mutant cancer cell lines; 15 male vs. 17 female lymphoblastoid cells; 24 acute lymphoid leukemia (ALL) vs. 24 acute myeloid leukemia (AML) cells. This evidence concerns the gene TP53 and acute myeloid leukemia.